Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Features

Does BEST-CLI Settle the Surgery vs Endovascular Question for CLTI?

L.A. McKeown

December 02, 2022

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

L.A. McKeown

November 18, 2022

News Conference News VIVA 2022

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

L.A. McKeown

November 04, 2022

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

L.A. McKeown

November 03, 2022

Presentation TCT 2022

TCT 207: Intravascular Lithotripsy for Calcified Peripheral Artery Disease (PAD) in Female vs Male Patients: Sex-Specific Analysis From the Disrupt PAD III Observational Study

Presenter: Sameer Nagpal

September 17, 2022

News Opinion CV Team Dispatch

September 2022 News Roundup

L.A. McKeown

September 01, 2022

News Daily News

Worse Complications After PVI in Women Highlight Research Gaps

L.A. McKeown

August 16, 2022

News Daily News

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

L.A. McKeown

August 05, 2022

News Daily News

High Lp(a) May Predict Risk of CV and Limb Events in PAD

L.A. McKeown

July 18, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for June 2022

Caitlin E. Cox

July 04, 2022

News Daily News

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

L.A. McKeown

June 29, 2022

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Conference News SCAI 2022

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

L.A. McKeown

May 23, 2022

News Conference News SCAI 2022

SAFE-PAD Provides More Long-term Safety Data for Paclitaxel

L.A. McKeown

May 22, 2022

Presentation Fellows 2022

Workup and Treatment of Lower-Extremity PAD: What All Interventionalists Need to Know

Presenter: Sahil Parikh

May 07, 2022

News Daily News

SCAI-Led Position Statement on CLTI Spotlights Multispeciality Involvement

L.A. McKeown

April 27, 2022

News Conference News ACC 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

L.A. McKeown

April 04, 2022

News Daily News

PAD Significantly Ups Morbidity and Mortality in AMICS

L.A. McKeown

March 29, 2022

Advertisement

Does BEST-CLI Settle the Surgery vs Endovascular Question for CLTI?

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

TCT 207: Intravascular Lithotripsy for Calcified Peripheral Artery Disease (PAD) in Female vs Male Patients: Sex-Specific Analysis From the Disrupt PAD III Observational Study

September 2022 News Roundup

Worse Complications After PVI in Women Highlight Research Gaps

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

High Lp(a) May Predict Risk of CV and Limb Events in PAD

TCTMD’s Top 10 Most Popular Stories for June 2022

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

SAFE-PAD Provides More Long-term Safety Data for Paclitaxel

Workup and Treatment of Lower-Extremity PAD: What All Interventionalists Need to Know

SCAI-Led Position Statement on CLTI Spotlights Multispeciality Involvement

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

PAD Significantly Ups Morbidity and Mortality in AMICS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content